Systemic and targeted therapy for biliary tract tumors and primary liver tumors

Surgical Oncology Clinics of North America

Volumn 23, Issue 2, 2014, Pages 369-381

  Thomas, Melanie Byrne ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bile duct cancer cholangiocarcinoma; Chemotherapy; Hepatocellular carcinoma; Systemic therapy; Targeted therapies

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOKINE RECEPTOR ANTAGONIST; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INTERFERON; IRINOTECAN; LAPATINIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAVITOCLAX; NK 4; NOLATREXED; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLATINUM COMPLEX; SELUMETINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BILIARY TRACT TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMORBIDITY; DOSE RESPONSE; GALLBLADDER CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; REVIEW; SYSTEMIC THERAPY;

BILE DUCT CANCER CHOLANGIOCARCINOMA; CHEMOTHERAPY; HEPATOCELLULAR CARCINOMA; SYSTEMIC THERAPY; TARGETED THERAPIES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; DRUG DELIVERY SYSTEMS; HUMANS; LIVER NEOPLASMS;

EID: 84896701861     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.11.004     Document Type: Review

References (83)

1. Blechacz B., Komuta M., Roskams T., et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011, 8:512-522.
2. Chung Y.E., Kim M.J., Park Y.N., et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009, 29:683-700.
3. Inui K., Yoshino J., Miyoshi H. Differential diagnosis and treatment of biliary strictures. Clin Gastroenterol Hepatol 2009, 7:S79-S83.
4. Motosugi U., Ichikawa T., Nakajima H., et al. Cholangiolocellular carcinoma of the liver: imaging findings. JComput Assist Tomogr 2009, 33:682-688.
5. Kim S.H., Lee W.J., Lim H.K., et al. Sclerosing hepatic carcinoma: helical CT features. Abdom Imaging 2007, 32:725-729.
6. Gu X.J., Wang B.F., Liu R. Application of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of hilar cholangiocarcinoma. Zhonghua Yi Xue Za Zhi 2012, 92:1409-1412. [in Chinese].
7. Alvaro D., Bragazzi M.C., Benedetti A., et al. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Dig Liver Dis 2011, 43:60-65.
8. Lee S.W., Kim H.J., Park J.H., et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. JGastroenterol 2010, 45:560-566.
9. Wehbe H., Henson R., Meng F., et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006, 66:10517-10524.
10. Fava G., Alpini G., Rychlicki C., et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res 2008, 68:6752-6761.
11. Marin J.J., Romero M.R., Briz O. Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem 2010, 17:709-740.
12. Namwat N., Amimanan P., Loilome W., et al. Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy 2008, 54:343-351.
13. Kongpetch S., Kukongviriyapan V., Prawan A., et al. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One 2012, 7:e34994.
14. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
15. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. NEngl J Med 2010, 362:1273-1281.
16. Lin M.H., Chen J.S., Chen H.H., et al. Aphase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003, 49:154-158.
17. Alberts S.R., Al-Khatib H., Mahoney M.R., et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005, 103:111-118.
18. Sasaki T., Isayama H., Nakai Y., et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012, 30:708-713.
19. Thongprasert S., Napapan S., Charoentum C., et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005, 16:279-281.
20. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. JClin Oncol 2005, 23:2332-2338.
21. Jang J.S., Lim H.Y., Hwang I.G., et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010, 65:641-647.
22. Gruenberger B., Schueller J., Heubrandtner U., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010, 11:1142-1148.
23. Nehls O., Oettle H., Hartmann J.T., et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008, 98:309-315.
24. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004, 101:578-586.
25. Feisthammel J., Schoppmeyer K., Mossner J., et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol 2007, 30:319-324.
26. Furuse J., Kasuga A., Takasu A., et al. Role of chemotherapy in treatments for biliary tract cancer. JHepatobiliary Pancreat Sci 2012, 19:337-341.
27. Eckmann K.R., Patel D.K., Landgraf A., et al. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 2011, 4:155-160.
28. Lubner S.J., Mahoney M.R., Kolesar J.L., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. JClin Oncol 2010, 28:3491-3497.
29. Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102:68-72.
30. El-Khoueiry A.B., Rankin C.J., Ben-Josef E., et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2012, 30:1646-1651.
31. Ramanathan R.K., Belani C.P., Singh D.A., et al. Aphase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009, 64:777-783.
32. Bekaii-Saab T., Phelps M.A., Li X., et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. JClin Oncol 2011, 29:2357-2363.
33. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. JClin Oncol 2006, 24:3069-3074.
34. Jensen L.H., Lindebjerg J., Ploen J., et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 2012, 23:2341-2346.
35. Lee J., Park S.H., Chang H.M., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012, 13:181-188.
36. Yi J.H., Thongprasert S., Lee J., et al. Aphase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012, 48:196-201.
37. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2study. Lancet Oncol 2010, 11:48-54.
38. Yoshikawa D., Ojima H., Iwasaki M., et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008, 98:418-425.
39. Yoshikawa D., Ojima H., Kokubu A., et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009, 100:1257-1266.
40. Fingas C.D., Mertens J.C., Razumilava N., et al. Targeting PDGFR-beta in cholangiocarcinoma. Liver Int 2012, 32:400-409.
41. Boonjaraspinyo S., Boonmars T., Wu Z., et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 2012, 33:1785-1802.
42. Fingas C.D., Bronk S.F., Werneburg N.W., et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011, 54:2076-2088.
43. Mertens J.C., Fingas C.D., Christensen J.D., et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 2013, 73:897-907.
44. Yoon J.H., Werneburg N.W., Higuchi H., et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002, 62:6500-6505.
45. Jan Y.Y., Yeh T.S., Yeh J.N., et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 2004, 240:89-94.
46. Terada T., Ashida K., Endo K., et al. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998, 33:325-331.
47. Lai G.H., Zhang Z., Shen X.N., et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 2005, 129:2047-2057.
48. Kiguchi K., Carbajal S., Chan K., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001, 61:6971-6976.
49. Leone F., Cavalloni G., Pignochino Y., et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006, 12:1680-1685.
50. Zhang Z., Oyesanya R.A., Campbell D.J., et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology 2010, 52:975-986.
51. Sirica A.E., Lai G.H., Endo K., et al. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002, 22:303-313.
52. Sirica A.E., Lai G.H., Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. JGastroenterol Hepatol 2001, 16:363-372.
53. Han C., Demetris A.J., Stolz D.B., et al. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. JBiol Chem 2006, 281:24831-24846.
54. Han C., Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. JBiol Chem 2005, 280:24053-24063.
55. Zhang Z., Lai G.H., Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004, 39:1028-1037.
56. Dobashi A., Imazu H., Tatsumi N., et al. Quantitative analysis of VEGF-C mRNA of extrahepatic cholangiocarcinoma with real-time PCR using samples obtained during endoscopic retrograde cholangiopancreatography. Scand J Gastroenterol 2013, 48:848-855.
57. Benckert C., Jonas S., Cramer T., et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003, 63:1083-1092.
58. Sugiyama H., Onuki K., Ishige K., et al. Potent invitro and invivo antitumor activityof sorafenib against human intrahepatic cholangiocarcinoma cells. JGastroenterol 2011, 46:779-789.
59. Wiedmann M.W., Mossner J. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets 2010, 11:834-850.
60. Meng F., Yamagiwa Y., Taffetani S., et al. IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol 2005, 289:C971-C981.
61. Tan F.L., Ooi A., Huang D., et al. p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer 2010, 126:2353-2361.
62. Horiuchi H., Kawamata H., Furihata T., et al. AMEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice. JExp Clin Cancer Res 2004, 23:599-606.
63. Horiuchi H., Kawamata H., Fujimori T., et al. AMEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003, 23:957-963.
64. Radaeva S., Ferreira-Gonzalez A., Sirica A.E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 1999, 29:1453-1462.
65. Terada T., Nakanuma Y., Sirica A.E. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998, 29:175-180.
66. Socoteanu M.P., Mott F., Alpini G., et al. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 2008, 14:2990-2994.
67. Ge X., Wang Y., Wang Y., et al. NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells. Dig Dis Sci 2013, 58:1636-1643.
68. Sia D., Hoshida Y., Villanueva A., et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013, 144:829-840.
69. Andersen J.B., Spee B., Blechacz B.R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012, 142:1021-1031.e15.
70. Tannapfel A., Sommerer F., Benicke M., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
71. El Khatib M., Kalnytska A., Palagani V., et al. Inhibition of hedgehog signaling attenuates carcinogenesis invitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013, 57:1035-1045.
72. Omenetti A., Diehl A.M. Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol 2011, 27:268-275.
73. Utispan K., Sonongbua J., Thuwajit P., et al. Periostin activates integrin alpha5beta1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int J Oncol 2012, 41:1110-1118.
74. Yeo W., Mok T.S., Zee B., et al. Arandomized phase III study of doxorubicin versuscisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. JNatl Cancer Inst 2005, 97:1532-1538.
75. Gish R.G., Porta C., Lazar L., et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. JClin Oncol 2007, 25:3069-3075.
76. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359:378-390.
77. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
78. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. JClin Oncol 2008, 26:2992-2998.
79. Thomas M.B., Morris J.S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. JClin Oncol 2009, 27:843-850.
80. Kaseb A.O., Garrett-Mayer E., Morris J.S., et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 2012, 82:67-74.
81. Boige V., Malka D., Bourredjem A., et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012, 17:1063-1072.
82. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110:1059-1067.
83. Bekaii-Saab T., Markowitz J., Prescott N., et al. Amulti-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009, 15:5895-5901.